CR10961A - Anticuerpos neutralizantes del citomegalovirus humano y su uso - Google Patents

Anticuerpos neutralizantes del citomegalovirus humano y su uso

Info

Publication number
CR10961A
CR10961A CR10961A CR10961A CR10961A CR 10961 A CR10961 A CR 10961A CR 10961 A CR10961 A CR 10961A CR 10961 A CR10961 A CR 10961A CR 10961 A CR10961 A CR 10961A
Authority
CR
Costa Rica
Prior art keywords
neutralizing antibodies
human
citomegalovirus
human citomegalovirus
antibodies
Prior art date
Application number
CR10961A
Other languages
English (en)
Inventor
Lanzavecchia Antonio
Macagno Annalisa
Original Assignee
Humabs Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37801734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR10961(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Humabs Llc filed Critical Humabs Llc
Publication of CR10961A publication Critical patent/CR10961A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La invencion se refiere a anticuerpos neutralizantes que son especificos para el citomegalovirus humano y se unen en alta afinidad asi como cedulas B inmortalizadas que producen dichos anticuerpos.
CR10961A 2007-01-04 2009-07-31 Anticuerpos neutralizantes del citomegalovirus humano y su uso CR10961A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0700133.2A GB0700133D0 (en) 2007-01-04 2007-01-04 Human cytomegalovirus neutralising antibodies and use thereof

Publications (1)

Publication Number Publication Date
CR10961A true CR10961A (es) 2009-11-20

Family

ID=37801734

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10961A CR10961A (es) 2007-01-04 2009-07-31 Anticuerpos neutralizantes del citomegalovirus humano y su uso

Country Status (32)

Country Link
US (4) US7955599B2 (es)
EP (3) EP2860189A3 (es)
JP (2) JP5710123B2 (es)
KR (2) KR101541927B1 (es)
CN (1) CN101657467B (es)
AU (1) AU2008204258B2 (es)
BR (1) BRPI0806185A2 (es)
CA (1) CA2673755C (es)
CO (1) CO6220862A2 (es)
CR (1) CR10961A (es)
CY (1) CY1114271T1 (es)
DK (1) DK2118140T3 (es)
EC (1) ECSP099547A (es)
ES (2) ES2426987T3 (es)
GB (1) GB0700133D0 (es)
GT (1) GT200900188A (es)
HK (2) HK1139158A1 (es)
HR (1) HRP20130877T1 (es)
IL (1) IL199585A (es)
MA (1) MA31225B1 (es)
MX (1) MX2009007320A (es)
MY (2) MY150709A (es)
NZ (1) NZ578844A (es)
PL (1) PL2118140T3 (es)
PT (2) PT2487187E (es)
RU (1) RU2469045C2 (es)
SG (3) SG191635A1 (es)
SI (1) SI2118140T1 (es)
TN (1) TN2009000285A1 (es)
UA (1) UA100682C2 (es)
WO (1) WO2008084410A2 (es)
ZA (1) ZA200905408B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2037959B1 (en) * 2006-06-07 2016-01-27 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
GB0700133D0 (en) * 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US8435510B2 (en) 2007-08-08 2013-05-07 Sutter West Bay Hospitals Platelet derived growth factor receptor supports cytomegalovirus infectivity
PE20141432A1 (es) 2008-07-16 2014-10-18 Inst Research In Biomedicine Anticuerpos neutralizantes de citomegalovirus humano
AU2012203417B2 (en) * 2008-07-16 2014-07-10 Institute For Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
ES2548014T3 (es) * 2008-07-16 2015-10-13 Institute For Research In Biomedicine Anticuerpos neutralizantes del citomegalovirus humano y uso de los mismos
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
MX2011000768A (es) 2008-07-25 2011-10-05 Inst Research In Biomedicine Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos.
KR101390015B1 (ko) 2009-04-01 2014-04-29 에베크 인코포레이티드 인간 사이토메갈로바이러스 ｇＢ 당단백질의 ＡＤ1 영역에 존재하는 특정한 불연속 에피토프에 결합하는 모노클로날 항체 및 그의 항원 결합성 단편
EA201270662A1 (ru) * 2009-12-23 2013-01-30 4-Антибоди Аг Связывающие элементы для человеческого цитамегаловируса
RU2613421C2 (ru) 2010-06-16 2017-03-16 ТРЕЛЛИС БАЙОСАЙЕНС, ЭлЭлСи Высокоаффинные антитела человека к белку gb цитомегаловирусу (cmv) человека
HUE044089T2 (hu) 2011-07-18 2019-09-30 Inst Res Biomedicine Neutralizáló anti-influenza A antitestek és alkalmazásaik
RU2014143251A (ru) 2012-03-28 2016-05-20 Дженентек, Инк. Антиидиотипические антитела к hcmv и их применение
WO2014099908A1 (en) * 2012-12-17 2014-06-26 Genentech, Inc. Methods for inhibiting viral infection in transplant patients
ES2837392T3 (es) 2013-10-02 2021-06-30 Medimmune Llc Anticuerpos anti-influenza A neutralizantes y usos de los mismos
CA2954780A1 (en) 2014-07-15 2016-01-21 Medimmune, Llc Neutralizing anti-influenza b antibodies and uses thereof
US20160069643A1 (en) * 2014-09-06 2016-03-10 Philip Lyren Weapon Targeting System
AU2016271323B2 (en) 2015-06-01 2022-08-25 Medimmune, Llc Neutralizing anti-influenza binding molecules and uses thereof
EA201891299A1 (ru) * 2016-01-08 2019-01-31 Аимм Терапьютикс Б.В. Терапевтические антитела к cd9
CN116271017A (zh) 2016-01-13 2023-06-23 免疫医疗有限责任公司 治疗甲型流感的方法
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
CA3019588A1 (en) 2016-04-20 2017-10-26 Merck Sharp & Dohme Corp. Cmv neutralizing antigen binding proteins
CN112004826B (zh) * 2018-02-05 2024-06-14 自由大学基金会 反向激动性抗us28抗体
CN109580944A (zh) * 2018-12-07 2019-04-05 潍坊医学院 一种人巨细胞病毒检测试纸及其制造方法
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN109738631A (zh) * 2019-01-21 2019-05-10 潍坊医学院 一种人巨细胞病毒IgM抗体检测试纸的制备方法
CN118465272A (zh) * 2019-12-04 2024-08-09 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途
US11857622B2 (en) 2020-06-21 2024-01-02 Pfizer Inc. Human cytomegalovirus GB polypeptide

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1061943A (en) 1964-09-10 1967-03-15 Carter S Ink Co Marking composition
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4294817A (en) 1977-11-25 1981-10-13 International Diagnostic Technology, Inc. Method of fluoro immunoassay
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US4313927A (en) 1979-10-19 1982-02-02 Ames-Yissum Ltd. Immunoassay method for detecting viral antibodies in whole blood samples
US4334016A (en) 1980-06-19 1982-06-08 The Wistar Institute Of Anatomy And Biology Human osteogenic sarcoma cell line and use thereof for immunofluorescent antibody test
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
FR2543570B1 (fr) 1983-03-31 1985-08-09 Pasteur Institut Anticorps monoclonaux anticytomegalovirus humains, hybridomes secreteurs de ces anticorps et polypeptides porteurs d'un determinant antigenique sequentiel de cytomegalovirus humains
US4617379A (en) 1983-06-14 1986-10-14 Miles Laboratories, Inc. High titer cytomegalovirus immune serum globulin
GB8404368D0 (en) 1984-02-20 1984-03-28 Cogent Ltd Monoclonal antibodies to human cytomegalovirus
US6100064A (en) 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
FR2563630B1 (fr) 1984-04-27 1988-02-19 Pasteur Institut Anticorps monoclonaux anticytomegalovirus et procedes pour le diagnostic in vitro des infections par les cytomegalovirus humains et d'une proteine-kinase inductible par les cytomegalovirus et susceptible d'etre reconnue par les susdits anticorps monoclonaux
US4783399A (en) 1984-05-04 1988-11-08 Scripps Clinic And Research Foundation Diagnostic system for the detection of cytomegalovirus
US4743562A (en) 1984-08-21 1988-05-10 The Board Of Trustees Of The Leland Stanford Junior University Purified human cytomegalovirus protein
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
EP0198086B1 (en) 1984-09-28 1991-01-16 Teijin Limited Mouse human hybridoma producing antivirus human antibody, process for its preparation, and antivirus human monoclonal antibody
US4808518A (en) 1985-02-11 1989-02-28 University Of Tennessee Research Corporation Recovery of cytomegalovirus antigen and use thereof in an assay
US4804627A (en) 1985-05-09 1989-02-14 Sloan-Kettering Institute For Cancer Research Method for cloning lymphoblastoid cells
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
WO1987003602A1 (en) 1985-12-06 1987-06-18 Teijin Limited Anticytomegaloviral human monoclonal antibody and process for its preparation
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5153311A (en) 1986-11-24 1992-10-06 The Children's Hospital, Incorporated Immunogenic glycoproteins of human cytomegalovirus gCII
US5126130A (en) 1986-11-24 1992-06-30 The Childrens Hospital Incorporated Monoclonal antibodies reactive with specific antigenic sites on human cytomegalovirus glycoprotein a
LU86752A1 (fr) 1987-01-30 1988-08-23 Univ Bruxelles Procede de production d'anticorps monoclonaux humains(igg)anticytomegalovirus et anticorps monoclonaux ainsi obtenus
FI884924A (fi) 1987-10-28 1989-04-29 Oncogen Humanimmuglobulin som producerats med hybrid-dna-teknik.
US5180813A (en) 1989-03-24 1993-01-19 University Of Iowa Research Foundation Early envelope glycoprotein of human cytomegalovirus (hmcv) and monoclonal antibodies to the glycoproteins
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
WO1991004277A1 (en) 1989-09-14 1991-04-04 Children's Biomedical Research Institute Monoclonal antibodies specific to cytomegalovirus glycoprotein
WO1991005876A1 (en) 1989-10-20 1991-05-02 Children's Biomedical Research Institute Human cytomegalovirus-specific monoclonal antibody cocktail
GB9008223D0 (en) 1990-04-11 1990-06-13 Royal Free Hosp School Med Improvements relating to the detection of viruses
DE4035174A1 (de) 1990-11-06 1992-05-07 Biotest Ag Verfahren zur bestimmung von proteinen in koerperfluessigkeiten und mittel zur durchfuehrung des verfahrens
US5997878A (en) 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
JPH053794A (ja) * 1991-06-26 1993-01-14 Green Cross Corp:The 抗サイトメガロウイルスヒトモノクローナル抗体およびその産生細胞
DE4128684A1 (de) 1991-08-29 1993-03-04 Behringwerke Ag Hcmv-spezifische peptide, mittel dazu und ihre verwendung
DE69227623T2 (de) 1992-04-10 1999-05-20 Erland Uppsala Hanas Verfahren zum Nachweis einer CMV-Infektion
SE9201281L (sv) 1992-04-23 1993-10-24 Bioinvent Int Ab Nya humana monoklonala antikroppar och förfarande för framställning därav
JPH05260961A (ja) * 1992-05-21 1993-10-12 Teijin Ltd サイトメガロウイルスに対するヒト・モノクローナル抗体を産生するハイブリドーマ
GB9221654D0 (en) * 1992-10-15 1992-11-25 Scotgen Ltd Recombinant human anti-cytomegalovirus antibodies
AU681115B2 (en) 1993-01-21 1997-08-21 Erna Moller Prevention and treatment of cytomegalovirus using aminopeptidase
US5750106A (en) * 1993-01-28 1998-05-12 Novartis Ag Human monoclonal antibodies to cytomegalovirus
WO1994016730A1 (en) 1993-01-28 1994-08-04 Sandoz Pharmaceutical Corporation Human monoclonal antibodies to cytomegalovirus
AU6777594A (en) 1993-04-30 1994-11-21 Scripps Research Institute, The Human monoclonal antibodies to human cytomegalovirus, and methods therefor
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
EP0702083A3 (de) 1994-07-26 1997-01-15 Biotest Ag Polypeptide und Fusionsproteine bestehend aus dem UL 57 Leserahmen bzw. dem C-terminalen Bereich des Tegumentproteins pp150 aus HCMV, entsprechende Oligonucleotide und Nachweis reagentien
US5783383A (en) 1995-05-23 1998-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of detecting cytomegalovirus (CMV)
US6019980A (en) 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US5800981A (en) 1996-02-22 1998-09-01 University Of Limburg Human cytomegalovirus antigen and its use
ATE225942T1 (de) 1996-07-12 2002-10-15 Organon Teknika Bv Peptidereagenz zum nachweis von humanem cytomegalovirus (cmv)
AU728285C (en) 1996-08-14 2002-02-21 Wistar Institute Of Anatomy And Biology, The Methods and compositions for preventing or retarding the development of atherosclerotic lesions
EP1003841A4 (en) 1997-01-30 2002-04-17 Cedars Sinai Medical Center CREATION OF A HSV-8 + LYMPHOMATORY CELL LINE, PRODUCT VIRUS, ANTIBODIES, DIAGNOSTIC METHOD AND KIT FOR DETECTING HSV-8 INFECTION
US6183752B1 (en) 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
AU8063798A (en) 1997-06-19 1999-01-04 Regents Of The University Of California, The Secretory immunoglobulin produced by single cells and methods for making and using same
JP2001512662A (ja) 1997-07-18 2001-08-28 コノート ラボラトリーズ リミテッド 呼吸器合胞体ウイルスのｇタンパク質をコードする核酸ワクチン
CA2309826A1 (en) 1997-11-14 1999-05-27 Connaught Laboratories Limited Alphavirus vectors for paramyxovirus vaccines
DE19756214C1 (de) 1997-12-17 1999-02-25 Biotest Ag Polypeptide mit Aminosäuresequenzen aus dem N-terminalen Bereich von gp116 und deren Verwendung bei der Diagnostik, Prophylaxe und Therapie
ATE226444T1 (de) 1998-03-12 2002-11-15 Genentech Inc Verwendung von fgf-5 polypetiden zur vorbeugung des absterbens retinaler neuronen und behandlung okularer krankheiten
JP2002519334A (ja) 1998-06-29 2002-07-02 ベルクター，ヴォルフガンク αエミッタとβエミッタとを主成分とする抗ウイルスおよび抗レトロウイルス放射免疫薬剤
RU2133472C1 (ru) 1998-09-16 1999-07-20 Унитарное государственное Московское предприятие по производству бактерийных препаратов Способ диагностики активной стадии цитомегаловирусной инфекции человека
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
ITMI20012160A1 (it) 2001-10-18 2003-04-18 Edoardo Marchisio Sistema immunoenzimatico per la caratterizzazione antigenica dell'infezione attiva da cytomegalovirus e cmv confirmation test
US6828113B2 (en) 2002-03-21 2004-12-07 Cornell Research Foundation, Inc. IgM antibodies to the 70 kDa heat shock protein as a marker for cytomegalovirus infection
CA2480811A1 (en) 2002-04-01 2003-10-16 Agensys, Inc. Nucleic acid and corresponding protein entitled 213p1f11 useful in treatment and detection of cancer
RU2239453C2 (ru) * 2002-12-03 2004-11-10 Федеральное государственное унитарное предприятие " Научно-производственное объединение по медицинским иммунобиологическим препаратам " Микроген" Препарат иммуноглобулина человека против цитомегаловируса и способ его получения
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
WO2004076645A2 (en) 2003-02-27 2004-09-10 University Of Massachusetts Compositions and methods for cytomegalovirus treatment
US20060216302A1 (en) 2003-02-28 2006-09-28 Robert Root-Bernstein Immunological markers
CN102863532A (zh) 2004-06-21 2013-01-09 米德列斯公司 干扰素α受体1抗体及其用途
BE1016287A6 (nl) 2004-07-14 2006-07-04 Picanol Nv Gaapvormingsonderdeel voor een weefmachine en weefmachine.
US7976845B2 (en) 2004-11-29 2011-07-12 The Council Of The Queensland Institute Of Medical Research Human cytomegalovirus immunotherapy
ES2546543T3 (es) 2005-03-14 2015-09-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anticuerpos monoclonales humanos contra los virus Hendra y Nipah
JP5431730B2 (ja) 2005-12-16 2014-03-05 リボバックス バイオテクノロジーズ ソシエテ アノニム 不死化された抗体分泌細胞を得る方法
WO2007094423A1 (ja) 2006-02-15 2007-08-23 Evec Incorporated ヒトサイトメガロウイルスに結合するヒトのモノクローナル抗体並びにその抗原結合部分
ES2549128T3 (es) 2006-05-19 2015-10-23 Technion Research And Development Foundation Ltd. Proteínas de fusión, usos de las mismas y procesos para producir las mismas
EP2037959B1 (en) 2006-06-07 2016-01-27 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
ATE503769T1 (de) 2006-12-15 2011-04-15 Ribovax Biotechnologies Sa Antikörper gegen das humane cytomegalie-virus (hcmv)
GB0700133D0 (en) * 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US7947274B2 (en) * 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
WO2008120203A2 (en) 2007-03-29 2008-10-09 Technion Research & Development Foundation Ltd. Antibodies and their uses for diagnosis and treatment of cytomegalovirus infection and associated diseases
US20080248042A1 (en) 2007-04-05 2008-10-09 Irccs Centro Di Riferimento Oncologico Di Aviano, Monoclonal antibody cross-reactive against infective agent causing a B-cell expansion and IgG-Fc
WO2009024445A1 (en) 2007-08-22 2009-02-26 Ribovax Biotechnologies Sa Antibodies against human cytomegalovirus (hcmv)
US7763261B2 (en) 2007-12-19 2010-07-27 Dcb-Usa Llc Anti-human cytomegalovirus antibodies
ES2548014T3 (es) 2008-07-16 2015-10-13 Institute For Research In Biomedicine Anticuerpos neutralizantes del citomegalovirus humano y uso de los mismos
PE20141432A1 (es) * 2008-07-16 2014-10-18 Inst Research In Biomedicine Anticuerpos neutralizantes de citomegalovirus humano

Also Published As

Publication number Publication date
JP5710123B2 (ja) 2015-04-30
EP2118140B1 (en) 2013-06-19
HK1174344A1 (en) 2013-06-07
EP2487187A3 (en) 2012-11-21
US20120076802A1 (en) 2012-03-29
EP2487187A2 (en) 2012-08-15
EP2860189A3 (en) 2015-07-29
RU2469045C2 (ru) 2012-12-10
US20080213265A1 (en) 2008-09-04
SI2118140T1 (sl) 2013-10-30
ES2426987T3 (es) 2013-10-28
TN2009000285A1 (en) 2010-12-31
CO6220862A2 (es) 2010-11-19
MA31225B1 (fr) 2010-03-01
US20130101604A1 (en) 2013-04-25
PT2118140E (pt) 2013-08-29
WO2008084410A2 (en) 2008-07-17
PL2118140T3 (pl) 2013-11-29
HRP20130877T1 (hr) 2013-10-25
UA100682C2 (ru) 2013-01-25
AU2008204258B2 (en) 2012-09-06
US9149524B2 (en) 2015-10-06
KR101659306B1 (ko) 2016-09-23
CN101657467B (zh) 2013-11-06
EP2860189A2 (en) 2015-04-15
MX2009007320A (es) 2010-02-22
KR20090127256A (ko) 2009-12-10
WO2008084410A3 (en) 2008-12-24
US7955599B2 (en) 2011-06-07
US8545848B2 (en) 2013-10-01
CN101657467A (zh) 2010-02-24
BRPI0806185A2 (pt) 2011-08-30
SG192399A1 (en) 2013-08-30
HK1139158A1 (en) 2010-09-10
JP2010516229A (ja) 2010-05-20
CA2673755C (en) 2016-04-05
JP2014141501A (ja) 2014-08-07
RU2009129403A (ru) 2011-02-10
EP2118140A2 (en) 2009-11-18
GB0700133D0 (en) 2007-02-14
CA2673755A1 (en) 2008-07-17
NZ578844A (en) 2012-08-31
KR101541927B1 (ko) 2015-08-05
ZA200905408B (en) 2010-05-26
GT200900188A (es) 2011-11-29
US8309089B2 (en) 2012-11-13
ES2526907T3 (es) 2015-01-16
EP2487187B1 (en) 2014-10-22
DK2118140T3 (da) 2013-07-01
KR20140101884A (ko) 2014-08-20
MY161200A (en) 2017-04-14
SG191635A1 (en) 2013-07-31
SG177943A1 (en) 2012-02-28
CY1114271T1 (el) 2016-08-31
US20140056914A1 (en) 2014-02-27
IL199585A (en) 2014-07-31
MY150709A (en) 2014-02-28
PT2487187E (pt) 2015-02-05
AU2008204258A1 (en) 2008-07-17
ECSP099547A (es) 2009-11-30

Similar Documents

Publication Publication Date Title
CR10961A (es) Anticuerpos neutralizantes del citomegalovirus humano y su uso
CY1121389T1 (el) Αντισωματα που δεσμευονται ειδικα με την α-τοξινη toy staphylococcus aureus και μεθοδοι χρησης
ECSP11010826A (es) Citomegalovirus humano que neutraliza anticuerpos y su uso
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
UY37083A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso
PE20151926A1 (es) Anticuerpos de receptores de antitransferrina y metodos de uso
CR20140585A (es) Proteinas de union a antigeno st2
CO6551674A2 (es) Anticuerpos anti-her3 y usos de los mismo
CO7101248A2 (es) Compuesos de tetrazolinona y su uso como pesticidas
CR20120522A (es) Pirrolobenzodiacepinas y conjugados de las mismas
BR112015003282A2 (pt) composições de cimento de geopolímero e métodos de uso
BR112014019331A2 (pt) anticorpos para cd47 e métodos de uso desses
CO6680688A2 (es) Anticuerpos para el receptor del factor de crecimiento epidérmico 3(her3)
CR10237A (es) Anticuerpos contra la il-22 humana y usos para los mismos
UY32971A (es) Proteínas de unión al antígeno de la il-23 humana
CR11658A (es) Anticuerpos dirigidos a angiopoietina 1 y angiopoietina 2 y usos de los mismos
CL2012000258A1 (es) Proceso para la preparacion de composicion de aglomerante hidraulico asperjable que contiene como principales componentes agua, agregados, aglomerante hidraulico, acelerador de fraguado, aglomerante hidraulico asperjable; composicion; y uso
HN2006037713A (es) Compuestos utiles en terapia
SV2010003593A (es) Nuevos herbicidas
HN2011000357A (es) Composiciones y metodos para anticuerpos que que se dirigen a la proteina de complemento c5
BR112013016242A2 (pt) método de cimentação e, composição de cimentação
CO6731068A2 (es) Arilpirrolodonas pesticidas
CO6410314A2 (es) Proteínas de unión a il-17
UY33124A (es) Agentes y epítopos enlazados a wise
AR091305A1 (es) ANTICUERPOS ANTI-IgE Y SUS METODOS DE USO